Press Releases

Press Releases

Nov 29, 2012
Summary ToggleEnzon Announces Special Dividend
PISCATAWAY, NJ -- (Marketwire) -- 11/29/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that its Board of Directors has authorized a special dividend of $2.00 per common share, payable on December 21, 2012 to shareholders of record as of December 10, 2012 .
Nov 8, 2012
Summary ToggleEnzon Announces Two Oral Presentations at the Symposium of Drug Delivery Systems in Nanjing, China
PISCATAWAY, NJ -- (Marketwire) -- 11/08/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced two oral presentations at the 2nd Annual Symposium of Drug Delivery Systems-2012, which is being held November 8-10 in Nanjing , China .
Oct 31, 2012
Summary ToggleEnzon Reports Third Quarter 2012 Results
PISCATAWAY, NJ -- (Marketwire) -- 10/31/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2012.
Sep 11, 2012
Summary ToggleEnzon to Present at 2012 World Congress and Expo on Biowaivers and Biosimilars
PISCATAWAY, NJ -- (Marketwire) -- 09/11/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it will present at the 2012 World Congress and Expo on Biowaivers and Biosimilars , which is being held September 10-12 in San Antonio, TX.
Aug 1, 2012
Summary ToggleEnzon Reports Second Quarter 2012 Results
PISCATAWAY, NJ -- (Marketwire) -- 08/01/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2012.
Jul 16, 2012
Summary ToggleEnzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting
PISCATAWAY, NJ -- (Marketwire) -- 07/16/12 -- Enzon Pharmaceuticals, Inc.
Jun 19, 2012
Summary ToggleEnzon Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
PISCATAWAY, NJ -- (Marketwire) -- 06/19/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced the presentation of results from a Phase I study of PEG-SN38 in children with recurrent or refractory neuroblastoma and other solid tumors.
Jun 4, 2012
Summary ToggleEnzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 ASCO Meeting
PISCATAWAY, NJ -- (MARKETWIRE) -- 06/04/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from the final analysis of a Phase II study in which PEG-SN38 demonstrated notable activity in patients with previously treated metastatic breast cancer.
May 7, 2012
Summary ToggleEnzon and Hisun Announce Strategic Alliance for Enzon's Customized PEGylation Linker Technology and Licensing Agreement for PEG-SN38 in China
PISCATAWAY, NJ and ZHEJIANG, CHINA -- (Marketwire) -- 05/07/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) and Zhejiang Hisun Pharmaceuticals Co.
May 2, 2012
Summary ToggleEnzon Reports First Quarter 2012 Results
PISCATAWAY, NJ -- (Marketwire) -- 05/02/12 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the first quarter of 2012.
Displaying 11 - 20 of 337 results